Efficacy of 177 Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, ISSN: 2542-4548, Vol: 5, Issue: 1, Page: 236-240
2021
- 9Citations
- 19Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef7
- Captures19
- Readers19
- 19
Case Description
A 62-year-old man presented with a history of atypical meningioma (World Health Organization grade II) and recurrent as anaplastic meningioma (World Health Organization grade III). His previous treatments included multiple surgical resections, fractionated radiation therapy, stereotactic radiosurgery, everolimus/octreotide long-acting release, bevacizumab, and hydroxyurea. Magnetic resonance imaging revealed rapid volumetric progression over the prior 9 months, with a near tripling in size from 29.9 cm 3 to 80.4 cm 3. Indium In 111 octreotide scanning confirmed the presence of somatostatin receptors within the tumor. Lutetium Lu 177 dotatate was administered intravenously at a dose of 200 mCi per dose every 8 weeks for 4 cycles. Treatment was tolerated very well, with no notable adverse events. Tumor volume initially increased to 98.3 cm 3 after cycle 1 of treatment and subsequently decreased to 91.2 cm 3 after cycle 2. Eight months after treatment onset, the tumor volume remained stable (93.4 cm 3 ).
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2542454820301995; http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.015; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85105849318&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33718799; https://linkinghub.elsevier.com/retrieve/pii/S2542454820301995; https://dx.doi.org/10.1016/j.mayocpiqo.2020.09.015
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know